Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

NCT00983346 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped Lab Staff that was required left the institution, therefore accrual closed prematurely

Conditions

Cancer
Myeloma
Multiple Myeloma

Interventions

DRUG: Bortezomib

Sponsor

University of Utah

Collaborators

[object Object]